Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Genetics
• Radiotherapy

Background:

• Brain metastasis is a frequent complication in non-small-cell lung cancer (NSCLC) with driver gene mutations, particularly anaplastic lymphoma kinase (ALK) gene rearrangement.
• While tyrosine kinase inhibitors (TKIs) are a focus of research, specific treatment strategies for brain metastasis in ALK-rearranged NSCLC remain under investigation.
• Further exploration is needed regarding the prognosis, the role of ALK-TKIs, and optimal combination therapies with radiotherapy for these patients.

Purpose of the Study:

• To review current data on the prognosis of patients with ALK-rearranged NSCLC and brain metastasis treated with ALK-TKIs.
• To evaluate the efficacy of ALK-TKIs, both as monotherapy and in combination with radiotherapy, for managing brain metastasis in NSCLC.
• To discuss the evolving treatment landscape, including the role of next-generation ALK-TKIs and radiotherapy modalities like stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT).

Main Methods:

• Review of retrospective clinical trial data concerning ALK-TKI treatment for brain metastasis in NSCLC.
• Analysis of treatment outcomes, including intracranial control rate, progression-free survival, and overall survival.
• Comparison of treatment strategies involving crizotinib and next-generation ALK-TKIs, with or without radiotherapy.

Main Results:

• In ALK inhibitor-naïve patients with brain metastasis, crizotinib combined with radiotherapy improved intracranial control and survival outcomes.
• Next-generation ALK-TKIs are increasingly used as first-line treatments and demonstrate significant intracranial efficacy, potentially allowing radiotherapy omission in refractory cases.
• For patients progressing on crizotinib, radiotherapy can enhance local control while systemic therapy continues; second/third-generation ALK inhibitors show strong efficacy against intracranial tumors.

Conclusions:

• Next-generation ALK-TKIs are becoming the preferred first-line treatment for ALK-rearranged NSCLC with brain metastasis, offering potent activity against intracranial disease.
• Radiotherapy, including SRS and WBRT, remains a crucial local treatment option, though its necessity may decrease with highly effective ALK-TKIs.
• Further large-scale prospective studies are required to definitively establish optimal drug and radiation combinations for managing brain metastasis in ALK-rearranged NSCLC.